By Adriano Marchese
Novavax Inc. said Wednesday that Canada’s health regulator has approved its Covid-19 vaccine in adolescents aged 12 through 17.
The vaccine developer said that Health Canada approved its supplement to a new drug submission for Nuvaxovid which works towards immunization to help prevent the coronavirus in individuals.
The approval was based on data from pediatric expansion of the phase 3 trial in the U.S. which has showed that effectiveness was higher in adolescents than in young adults.
Trials have found that protective efficacy was of 79.5% overall at a time when the Delta variant was the predominant circulating strain.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
12-07-22 1018ET